Find a Clinical Trial Clinical trials are an important option to consider for your prostate cancer treatment. Use our clinical trial finder tool to see if a clinical trial may be right for you. Jump To Jump To Featured Clinical Trials Clinical Trials in the News More Information Clinical trials have helped hundreds of thousands of people – who are alive today – because new, more effective treatments became available. It’s important to take charge of your health and educate yourself about clinical trials you are eligible for based on your current situation.Get matched to a prostate cancer clinical trial that’s right for you! Use the clinical trial search tool below and print out your results to discuss with your treatment team or contact the study coordinators directly. Featured clinical trials Below are featured clinical trials you may be interested in learning more about. Be sure to use ZERO’s clinical trial finder above or visit www.clinicaltrials.gov to learn about all prostate cancer clinical trials you may be eligible for. You can use the results of these clinical trial finder tools to have conversations with your doctor. Eli Lilly Clinical Trial Eli Lilly is conducting a clinical trial research study for cancer patients with high-risk, metastatic, and hormone-sensitive prostate cancer. Participants in this study will be given a combination of investigational medications to determine if they will delay the time before cancer worsens. Pfizer Clinical Study This study is evaluating if an investigational (study) oral medicine is safe and effective for the treatment of metastatic castration resistant prostate cancer (mCRPC). The study is comprised of 2 parts: Part 1 compared different dose levels of the study medicine for tolerability and effectiveness. Part 2 will further evaluate the optimal dose level determined in Part 1; In Part 2 approximately 80 participants will be enrolled. Participants will be randomly assigned to receive the current standard-of care medicine (enzalutamide) or the study medicine in combination with the current standard-of-care medicine (enzalutamide). Half of participants will receive enzalutamide, and half will receive the study medicine plus enzalutamide. If you are not initially assigned to receive study medicine and tests show that your cancer has progressed during your time in the study, you will have the option to begin taking the study medicine in addition to enzalutamide. The PROMISE Registry The PROMISE Registry is a long-term observational study led by Heather Cheng, MD, PhD, Fred Hutch Cancer Center, University of Washington and Channing Paller, MD, Sibley Kimmel Comprehensive Cancer Center, Johns Hopkins University. Drs. Cheng and Paller seek to better understand how specific genetic profiles can: Influence the susceptibility of men to prostate cancer, impact the effectiveness of existing treatments, improve guidance for different and/or new treatment options, suggest precise areas to explore for new discoveries. PROMISE is an important next step in the fight against prostate cancer. PROMISE aims to bring precision medicine to the prostate cancer treatment much the way the research community has done for the treatment of breast cancer. TAMARACK The TAMARACK study uses a test drug that is an Anti-body Drug Conjugate, or ADC, as a potential treatment option for metastatic castrate resistant prostate cancer. An ADC is an antibody with an anti-cancer drug attached. The antibody portion of the ADC brings the anti-cancer drug specifically to the cancer cell, where it will attach to a protein on the outside of the cancer cell. It causes damage leading to the death of the cancer cell. The antibody is specifically targeted to enter cancer cells. The study compares two dose levels of the test drug and evaluates effectiveness and side effects. If your prostate cancer is worsening, you may be eligible. Learn more at clinicaltrials.gov. Clinical trials in the news Carolina Strong: Cancer survivor spreads hope, awareness Bob Lane, a prostate cancer survivor, is dedicating his time to raise awareness and support fellow patients, offering them guidance and encouragement as they navigate their journeys through the disease. 1 in 8 men will be diagnosed with prostate cancer. Screenings can help catch it early. When Screening for Prostate Cancer Comes Too Late Prostate cancer survivor pushes others to have regular screenings Local Run/Walk helping in the battle against prostate cancer Learn more about clinical trials Find out more information about clinical trials, including the types and phases of trials, as well as the patient protections in place. Clinical Trials Information
Clinical trials have helped hundreds of thousands of people – who are alive today – because new, more effective treatments became available. It’s important to take charge of your health and educate yourself about clinical trials you are eligible for based on your current situation.Get matched to a prostate cancer clinical trial that’s right for you! Use the clinical trial search tool below and print out your results to discuss with your treatment team or contact the study coordinators directly.
Featured clinical trials Below are featured clinical trials you may be interested in learning more about. Be sure to use ZERO’s clinical trial finder above or visit www.clinicaltrials.gov to learn about all prostate cancer clinical trials you may be eligible for. You can use the results of these clinical trial finder tools to have conversations with your doctor. Eli Lilly Clinical Trial Eli Lilly is conducting a clinical trial research study for cancer patients with high-risk, metastatic, and hormone-sensitive prostate cancer. Participants in this study will be given a combination of investigational medications to determine if they will delay the time before cancer worsens. Pfizer Clinical Study This study is evaluating if an investigational (study) oral medicine is safe and effective for the treatment of metastatic castration resistant prostate cancer (mCRPC). The study is comprised of 2 parts: Part 1 compared different dose levels of the study medicine for tolerability and effectiveness. Part 2 will further evaluate the optimal dose level determined in Part 1; In Part 2 approximately 80 participants will be enrolled. Participants will be randomly assigned to receive the current standard-of care medicine (enzalutamide) or the study medicine in combination with the current standard-of-care medicine (enzalutamide). Half of participants will receive enzalutamide, and half will receive the study medicine plus enzalutamide. If you are not initially assigned to receive study medicine and tests show that your cancer has progressed during your time in the study, you will have the option to begin taking the study medicine in addition to enzalutamide. The PROMISE Registry The PROMISE Registry is a long-term observational study led by Heather Cheng, MD, PhD, Fred Hutch Cancer Center, University of Washington and Channing Paller, MD, Sibley Kimmel Comprehensive Cancer Center, Johns Hopkins University. Drs. Cheng and Paller seek to better understand how specific genetic profiles can: Influence the susceptibility of men to prostate cancer, impact the effectiveness of existing treatments, improve guidance for different and/or new treatment options, suggest precise areas to explore for new discoveries. PROMISE is an important next step in the fight against prostate cancer. PROMISE aims to bring precision medicine to the prostate cancer treatment much the way the research community has done for the treatment of breast cancer. TAMARACK The TAMARACK study uses a test drug that is an Anti-body Drug Conjugate, or ADC, as a potential treatment option for metastatic castrate resistant prostate cancer. An ADC is an antibody with an anti-cancer drug attached. The antibody portion of the ADC brings the anti-cancer drug specifically to the cancer cell, where it will attach to a protein on the outside of the cancer cell. It causes damage leading to the death of the cancer cell. The antibody is specifically targeted to enter cancer cells. The study compares two dose levels of the test drug and evaluates effectiveness and side effects. If your prostate cancer is worsening, you may be eligible. Learn more at clinicaltrials.gov.
Clinical trials in the news Carolina Strong: Cancer survivor spreads hope, awareness Bob Lane, a prostate cancer survivor, is dedicating his time to raise awareness and support fellow patients, offering them guidance and encouragement as they navigate their journeys through the disease. 1 in 8 men will be diagnosed with prostate cancer. Screenings can help catch it early. When Screening for Prostate Cancer Comes Too Late Prostate cancer survivor pushes others to have regular screenings Local Run/Walk helping in the battle against prostate cancer
Learn more about clinical trials Find out more information about clinical trials, including the types and phases of trials, as well as the patient protections in place. Clinical Trials Information
